US Stock Futures Up Ahead Of Existing-Home Sales Data

Loading...
Loading...
Pre-open movers
US stock futures traded higher in early pre-market trade. The Chicago Fed National Activity Index for November will be released at 8:30 a.m. ET, while existing home sales data for November will be released at 10:00 a.m. ET. Futures for the Dow Jones Industrial Average jumped 50 points to 17,811.00, while the Standard & Poor's 500 index futures rose 5.10 points to 2,072.20. Futures for the Nasdaq 100 index climbed 12 points to 4,294.75.
A Peek Into Global Markets
European markets were higher today, with the Spanish Ibex Index gaining 0.27%, STOXX Europe 600 Index rising 0.57%. German DAX 30 index climbed 0.89%, French CAC 40 Index gained 0.90% and London's FTSE 100 Index rose 0.70%. In Asian markets, Japan's Nikkei Stock Average rose 0.08%, Hong Kong's Hang Seng Index climbed 1.26%, China's Shanghai Composite Index climbed 0.61% and India's Sensex jumped 1.21%.
Broker Recommendation
Analysts at Longbow Research downgraded
Western Digital CorporationWDC
from Buy to Neutral and removed the price target of $110. Western Digital's shares closed at $113.88 yesterday.
Breaking news
  • Oncolytics Biotech Inc. ONCY today announced that it has submitted applications for Orphan Designation to the European Medicines Agency ("EMA") for REOLYSIN for the treatment of pancreatic and ovarian cancers. To read the full news, click here.
  • Achillion Pharmaceuticals, Inc. ACHN today announced positive interim results from two studies supporting a short duration, potentially best-in-disease regimen of its proprietary NS5A and nucleotide inhibitors, ACH-3102 and ACH-3422. To read the full news, click here.
  • Abengoa SA ABGB technology solutions for sustainability in the energy and environment sectors, has been selected by Endesa to develop a new electric transmission project in southern Chile that will connect the Hydro Los Cóndores plant with Ancoa substation. To read the full news, click here.
  • BioCryst Pharmaceuticals, Inc., BCRX today announced that the U.S. Food and Drug Administration (FDA) has approved RAPIVAB (peramivir injection), an intravenous (i.v.) neuraminidase inhibitor for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days. To read the full news, click here.
Loading...
Loading...
Posted In: NewsEurozoneFuturesGlobalPre-Market OutlookMarketsLongbow ResearchUS Stock Futures
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...